PMCB 8-K Summary (Oct 30, 2025)
PharmaCyte Biotech, Inc. stockholders approved two critical proposals at the Special Meeting:
- Financing Authorization: Approved the issuance of Common Stock underlying preferred stock/warrants from the August 17, 2025 financing, necessary for Nasdaq Listing Rule 5635(d) compliance.
- Equity Expansion: Approved an amendment to the 2022 Equity Incentive Plan, increasing the share pool available for awards by 2,250,000 shares.
Quorum was achieved with ~37.1% of outstanding shares represented.
Investor Focus: The company secured nec
...